Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Lacouture

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
American Journal of Clinical Dermatology|October 31, 2018
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and NailsMario Lacouture, Vincent Sibaud
Clinical Genitourinary Cancer|August 21, 2009
Eosinophilic rash secondary to temsirolimusMona Gandhi, Timothy Kuzel, Mario Lacouture
Archives of Dermatology|June 20, 2007
The era of targeted therapies: increasing role for novel oncologic drugs in dermatologyLiliana Montella, Giovannella Palmieri, Mario Lacouture
Journal of the National Comprehensive Cancer Network : JNCCN|August 12, 2008
The role of inhibitors of the epidermal growth factor in management of head and neck cancerBruce Brockstein, Mario Lacouture, Mark Agulnik
Acta Oncologica (Stockholm, Sweden)|June 11, 2014
Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trialsRaji Shameem, Mario Lacouture, Shenhong Wu
Cancer Investigation|January 31, 2015
Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patientsRaji Shameem, Mario Lacouture, Shenhong Wu
The American Journal of Dermatopathology|August 2, 2007
p63 in Primary Cutaneous CarcinosarcomaKi-Young Suh, Mario Lacouture, Pedram Gerami
Clinical Breast Cancer|December 29, 2015
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series AnalysisMarissa D Friedman, Mario Lacouture, Chau Dang
JCO Precision Oncology|March 26, 2019
Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in <i>BRAF</i> V600E colorectal cancerSebastian Mondaca, Mario Lacouture, Jonathan Hersch, et al.
Clinical Journal of Oncology Nursing|July 24, 2018
Radiation Dermatitis: A Prevention Protocol for Patients With Breast CancerAnna S Lucas, Mario Lacouture, Susan M Schneider
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Dermatology|October 31, 2018
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and NailsMario Lacouture, Vincent Sibaud
Clinical Genitourinary Cancer|August 21, 2009
Eosinophilic rash secondary to temsirolimusMona Gandhi, Timothy Kuzel, Mario Lacouture
Archives of Dermatology|June 20, 2007
The era of targeted therapies: increasing role for novel oncologic drugs in dermatologyLiliana Montella, Giovannella Palmieri, Mario Lacouture
Journal of the National Comprehensive Cancer Network : JNCCN|August 12, 2008
The role of inhibitors of the epidermal growth factor in management of head and neck cancerBruce Brockstein, Mario Lacouture, Mark Agulnik
Acta Oncologica (Stockholm, Sweden)|June 11, 2014
Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trialsRaji Shameem, Mario Lacouture, Shenhong Wu
Cancer Investigation|January 31, 2015
Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patientsRaji Shameem, Mario Lacouture, Shenhong Wu
The American Journal of Dermatopathology|August 2, 2007
p63 in Primary Cutaneous CarcinosarcomaKi-Young Suh, Mario Lacouture, Pedram Gerami
Clinical Breast Cancer|December 29, 2015
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series AnalysisMarissa D Friedman, Mario Lacouture, Chau Dang
JCO Precision Oncology|March 26, 2019
Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in <i>BRAF</i> V600E colorectal cancerSebastian Mondaca, Mario Lacouture, Jonathan Hersch, et al.
Clinical Journal of Oncology Nursing|July 24, 2018
Radiation Dermatitis: A Prevention Protocol for Patients With Breast CancerAnna S Lucas, Mario Lacouture, Susan M Schneider
Pageof 6